ArticlePloS one2011
Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03626090 (Mesenchymal Stem Cell Therapy for Liver Cirrhosis), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mesenchymal Stem Cell Therapy for Liver Cirrhosis: A Phase I/II Study
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Drug-induced liver injury secondary to anakinra in a patient with systemic juvenile idiopathic arthritis-Case report and literature overview.Canadian liver journal · 2025Article
- Therapeutic strategies to improve liver regeneration after hepatectomy.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Article
- Potential advantages of genetically modified mesenchymal stem cells in the treatment of acute and chronic liver diseases.Stem cell research & therapy · 2023Review
- Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy.Hepatology communications · 2022Article
- Lipoproteins Cause Bone Resorption in a Mouse Model ofFrontiers in microbiology · 2022Article
- Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness.Stem cell reviews and reports · 2020Review
- T. gondii infection induces IL-1R dependent chronic cachexia and perivascular fibrosis in the liver and skeletal muscle.Scientific reports · 2020Article
- Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients.World journal of gastroenterology · 2020Article
- A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa.Scientific reports · 2019Article
- The YIN and YANG of lipoproteins in developing and preventing infectious arthritis by Staphylococcus aureus.PLoS pathogens · 2019Article
- Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner.International journal of molecular sciences · 2019Article
- Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure.Experimental and therapeutic medicine · 2017Article
- Sustained Inhibition of Proliferative Response After Transient FGF Stimulation Is Mediated by Interleukin 1 Signaling.Journal of cellular physiology · 2016Article
- The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration.BioMed research international · 2016Review
- Monocyte chemoattractant protein-1 is not required for liver regeneration after partial hepatectomy.Journal of inflammation (London, England) · 2016Article
- Candida albicans colonization and dissemination from the murine gastrointestinal tract: the influence of morphology and Th17 immunity.Cellular microbiology · 2015Article
- Stimulation of Proliferation and Migration of Mouse Macrophages by Type B CpG-ODNs Is F-Spondin and IL-1Ra Dependent.PloS one · 2015Article
- IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice.PloS one · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytokine administration is a potential therapy for acute liver failure by reducing inflammatory responses and favour hepatocyte regeneration. The aim of this study was to evaluate the role of interleukin-1 receptor antagonist (IL-1ra) during liver regeneration and to study the effect of a recombinant human IL-1ra on liver regeneration.
methodsWe performed 70%-hepatectomy in wild type (WT) mice, IL-1ra knock-out (KO) mice and in WT mice treated by anakinra. We analyzed liver regeneration at regular intervals by measuring the blood levels of cytokines, the hepatocyte proliferation by bromodeoxyuridin (BrdU) incorporation, proliferating cell nuclear antigen (PCNA) and Cyclin D1 expression. The effect of anakinra on hepatocyte proliferation was also tested in vitro using human hepatocytes.
resultsAt 24h and at 48 h after hepatectomy, IL-1ra KO mice had significantly higher levels of pro-inflammatory cytokines (IL-6, IL-1β and MCP-1) and a reduced and delayed hepatocyte proliferation measured by BrdU incorporation, PCNA and Cyclin D1 protein levels, when compared to WT mice. IGFBP-1 and C/EBPβ expression was significantly decreased in IL-1ra KO compared to WT mice. WT mice treated with anakinra showed significantly decreased levels of IL-6 and significantly higher hepatocyte proliferation at 24h compared to untreated WT mice. In vitro, primary human hepatocytes treated with anakinra showed significantly higher proliferation at 24h compared to hepatocytes without treatment.
conclusionIL1ra modulates the early phase of liver regeneration by decreasing the inflammatory stress and accelerating the entry of hepatocytes in proliferation. IL1ra might be a therapeutic target to improve hepatocyte proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.